ID: ALA289469

Max Phase: Approved

First Approval: 1993

Molecular Formula: C18H24N4O

Molecular Weight: 312.42

Molecule Type: Small molecule

Representations

Synonyms (6): Granisetron | APF-530 | APF530 | BRL 43694 | BRL-43694 | LY-278584
Synonyms from Alternative Forms(6):

Trade Names(3): Kytril | Sancuso | Sustol

Canonical SMILES:  CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2

Standard InChI:  InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)

Standard InChI Key:  MFWNKCLOYSRHCJ-UHFFFAOYSA-N

Molecule Features

Natural Product: Yes

Oral: Yes

Chemical Probe: No

Parenteral: Yes

Molecule Type: Small molecule

Topical: Yes

First In Class: No

Black Box: No

Chirality: Yes

Availability: Yes

Prodrug: No

Properties

Molecular Weight: 312.42

Molecular Weight (Monoisotopic): 312.1950

AlogP: 2.32

#Rotatable Bonds: 2

Polar Surface Area: 50.16

Molecular Species: BASE

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.00

CX LogP: 1.88

CX LogD: 0.27

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.93

Np Likeness Score: -1.06

References

1. Bermudez J, King F, Sanger G.  (1992)  Indazole and indoline as aromatic bioisosteres in the imidazole class of serotonin 5-HT3 receptor antagonists,  2  (12): [10.1016/S0960-894X(00)80418-7]

2. Fludzinski P, Evrard DA, Bloomquist WE, Lacefield WB, Pfeifer W, Jones ND, Deeter JB, Cohen ML..  (1987)  Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor.,  30  (9): [PMID:3625701] [10.1021/jm00392a001]

3. Cappelli A, Anzini M, Vomero S, Canullo L, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Bruni G, Romeo MR, Giorgi G, Donati A..  (1999)  Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.,  42  (9): [PMID:10229626] [10.1021/jm981112s]

4. Hibert MF, Hoffmann R, Miller RC, Carr AA..  (1990)  Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.,  33  (6): [PMID:2342053] [10.1021/jm00168a011]

5. Iriepa I, Villasante FJ, Gálvez E, Labeaga L, Innerarity A, Orjales A..  (2002)  Synthesis and pharmacology of isoquinuclidine derivatives as 5-HT(3) ligands.,  12  (2): [PMID:11755351] [10.1016/s0960-894x(01)00693-x]

6. Bermudez J, Fake CS, Joiner GF, Joiner KA, King FD, Miner WD, Sanger GJ..  (1990)  5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.,  33  (7): [PMID:2362270] [10.1021/jm00169a016]

7. Bermudez J, Fake CS, Joiner GF, Joiner KA, King FD, Miner WD, Sanger GJ..  (1990)  5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.,  33  (7): [PMID:2362270] [10.1021/jm00169a016]

8. Bermudez J, Dabbs S, Joiner KA, King FD..  (1990)  5-Hydroxytryptamine (5-HT3) receptor antagonists. 2. 1-Indolinecarboxamides.,  33  (7): [PMID:2362271] [10.1021/jm00169a017]

9. Schaus JM, Thompson DC, Bloomquist WE, Susemichel AD, Calligaro DO, Cohen ML..  (1998)  Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.,  41  (11): [PMID:9599243] [10.1021/jm970857f]

10. Doll F, Dolci L, Valette H, Hinnen F, Vaufrey F, Guenther I, Fuseau C, Coulon C, Bottlaender M, Crouzel C..  (1999)  Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.,  42  (12): [PMID:10377231] [10.1021/jm9910223]

11. Bermudez J, Gaster L, Gregory J, Jerman J, Joiner G, King F, Rahman S.  (1994)  Synthesis and 5-HT3 receptor antagonist potency of novel (endo) 3,9-diazabicyclo[3.3.1]nonan-7-amino derivatives,  4  (20): [10.1016/S0960-894X(01)80393-0]

12. Clark RD, Miller AB, Berger J, Repke DB, Weinhardt KK, Kowalczyk BA, Eglen RM, Bonhaus DW, Lee CH, Michel AD..  (1993)  2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.,  36  (18): [PMID:8410977] [10.1021/jm00070a008]

13. Sato Y, Yamada M, Yoshida S, Soneda T, Ishikawa M, Nizato T, Suzuki K, Konno F..  (1998)  Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.,  41  (16): [PMID:9685241] [10.1021/jm9801004]

14. Rival Y, Hoffmann R, Didier B, Rybaltchenko V, Bourguignon JJ, Wermuth CG..  (1998)  5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists.,  41  (3): [PMID:9464362] [10.1021/jm9705418]

15. Robertson DW, Bloomquist W, Cohen ML, Reid LR, Schenck K, Wong DT..  (1990)  Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.,  33  (12): [PMID:2258903] [10.1021/jm00174a013]

16. Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, Tran O, Wright N, Gordon JC..  (2001)  The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.,  11  (3): [PMID:11212100] [10.1016/s0960-894x(00)00670-3]

17. Kishibayashi N, Miwa Y, Hayashi H, Ishii A, Ichikawa S, Nonaka H, Yokoyama T, Suzuki F..  (1993)  5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.,  36  (22): [PMID:8230119] [10.1021/jm00074a009]

18. Heidempergher F, Pillan A, Pinciroli V, Vaghi F, Arrigoni C, Bolis G, Caccia C, Dho L, McArthur R, Varasi M..  (1997)  Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.,  40  (21): [PMID:9341912] [10.1021/jm970060o]

19. van Wijngaarden I, Hamminga D, van Hes R, Standaar PJ, Tipker J, Tulp MT, Mol F, Olivier B, de Jonge A..  (1993)  Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.,  36  (23): [PMID:8246239] [10.1021/jm00075a026]

20. Cavalli A, Poluzzi E, De Ponti F, Recanatini M..  (2002)  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.,  45  (18): [PMID:12190308] [10.1021/jm0208875]

21. Kaumann A, King F, Young R.  (1992)  Indazole as an indole bioisostere: 5-HT4 receptor antagonism.,  2  (5): [10.1016/S0960-894X(00)80160-2]

22. Blum E, Buchheit K, Buescher H, Gamse R, Kloeppner E, Meigel H, Papageorgiou C, Waelchli R, Revesz L.  (1992)  Design and synthesis of novel ligands for the 5-HT3 and the 5-HT4 receptor,  2  (5): [10.1016/S0960-894X(00)80170-5]

23. Hayashi H, Miwa Y, Miki I, Ichikawa S, Yoda N, Ishii A, Kono M, Suzuki F..  (1992)  5-HT3 receptor antagonists. 1. New quinoline derivatives.,  35  (26): [PMID:1479589] [10.1021/jm00104a016]

24. López-Rodríguez ML, Benhamú B, Morcillo MJ, Tejada ID, Orensanz L, Alfaro MJ, Martín MI..  (1999)  Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT(3) receptors.,  42  (24): [PMID:10585211] [10.1021/jm991076c]

25. Bermudez J, Gregory J, King F, Starr S, Summersell R.  (1992)  3-oxagranatane (3-oxa-9-azabicyclo[3.3.1]nonane) derivatives as highly potent serotonin 5-Ht3 receptor antagonists.,  2  (6): [10.1016/S0960-894X(01)81189-6]

26. Bermudez J, Gregory J, King F, Starr S, Summersell R.  (1992)  3-oxagranatane (3-oxa-9-azabicyclo[3.3.1]nonane) derivatives as highly potent serotonin 5-Ht3 receptor antagonists.,  2  (6): [10.1016/S0960-894X(01)81189-6]

27. Orjales A, Mosquera R, Labeaga L, Rodes R..  (1997)  New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.,  40  (4): [PMID:9046349] [10.1021/jm960442e]

28. Hayashi H, Miwa Y, Ichikawa S, Yoda N, Miki I, Ishii A, Kono M, Yasuzawa T, Suzuki F..  (1993)  5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.,  36  (5): [PMID:8496941] [10.1021/jm00057a011]

29. Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Bruni G, Romeo MR, Menziani MC, De Benedetti PG, Langer T..  (1998)  Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.,  41  (5): [PMID:9513601] [10.1021/jm970645i]

30. Youssefyeh RD, Campbell HF, Klein S, Airey JE, Darkes P, Powers M, Schnapper M, Neuenschwander K, Fitzpatrick LR, Pendley CE..  (1992)  Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.,  35  (5): [PMID:1312602] [10.1021/jm00083a014]

31. Youssefyeh RD, Campbell HF, Airey JE, Klein S, Schnapper M, Powers M, Woodward R, Rodriguez W, Golec S, Studt W..  (1992)  Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.,  35  (5): [PMID:1548679] [10.1021/jm00083a015]

32. Rajamani R, Tounge BA, Li J, Reynolds CH..  (2005)  A two-state homology model of the hERG K+ channel: application to ligand binding.,  15  (6): [PMID:15745831] [10.1016/j.bmcl.2005.01.008]

33. Cappelli A, Gallelli A, Manini M, Anzini M, Mennuni L, Makovec F, Menziani MC, Alcaro S, Ortuso F, Vomero S..  (2005)  Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties.,  48  (10): [PMID:15887964] [10.1021/jm0493461]

34. Tobita M, Nishikawa T, Nagashima R..  (2005)  A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.,  15  (11): [PMID:15911273] [10.1016/j.bmcl.2005.03.080]

35. Yoshida S, Watanabe T, Sato Y..  (2007)  Regulatory molecules for the 5-HT3 receptor ion channel gating system.,  15  (10): [PMID:17391967] [10.1016/j.bmc.2007.02.054]

36. Moda TL, Montanari CA, Andricopulo AD..  (2007)  Hologram QSAR model for the prediction of human oral bioavailability.,  15  (24): [PMID:17870541] [10.1016/j.bmc.2007.08.060]

37. Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, Sun Y, He Z..  (2009)  First-principle, structure-based prediction of hepatic metabolic clearance values in human.,  44  (4): [PMID:18768239] [10.1016/j.ejmech.2008.07.027]

38. Ermondi G, Visentin S, Caron G..  (2009)  GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.,  44  (5): [PMID:19110341] [10.1016/j.ejmech.2008.11.009]

39. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A..  (2009)  Physicochemical determinants of human renal clearance.,  52  (15): [PMID:19445515] [10.1021/jm900403j]

40. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD..  (2010)  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,  53  (3): [PMID:20070106] [10.1021/jm901371v]

41. Vernekar SK, Hallaq HY, Clarkson G, Thompson AJ, Silvestri L, Lummis SC, Lochner M..  (2010)  Toward biophysical probes for the 5-HT3 receptor: structure-activity relationship study of granisetron derivatives.,  53  (5): [PMID:20146481] [10.1021/jm901827x]

42. Guerra A, Campillo NE, Páez JA..  (2010)  Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,  45  (3): [PMID:20022146] [10.1016/j.ejmech.2009.11.034]

43. Moura Barbosa AJ, De Rienzo F, Ramos MJ, Menziani MC..  (2010)  Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.,  45  (11): [PMID:20724042] [10.1016/j.ejmech.2010.07.039]

44. Alelyunas YW, Empfield JR, McCarthy D, Spreen RC, Bui K, Pelosi-Kilby L, Shen C..  (2010)  Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.,  20  (24): [PMID:21055935] [10.1016/j.bmcl.2010.10.068]

45. PubChem BioAssay data set, 

46. Obach RS, Lombardo F, Waters NJ..  (2008)  Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.,  36  (7): [PMID:18426954] [10.1124/dmd.108.020479]

47. Manning DD, Cioffi CL, Usyatinsky A, Fitzpatrick K, Masih L, Guo C, Zhang Z, Choo SH, Sikkander MI, Ryan KN, Naginskaya J, Hassler C, Dobritsa S, Wierschke JD, Earley WG, Butler AS, Brady CA, Barnes NM, Cohen ML, Guzzo PR..  (2011)  Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.,  21  (1): [PMID:21146988] [10.1016/j.bmcl.2010.11.080]

48. Sinha N, Sen S..  (2011)  Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.,  46  (2): [PMID:21185626] [10.1016/j.ejmech.2010.11.042]

49. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF..  (2004)  Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.,  1  (4): [PMID:16472241] [10.2174/1570163043334794]

50. Unpublished dataset, 

51.  (2008)  Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, 

52. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

53. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

54. Simonin J, Vernekar SK, Thompson AJ, Hothersall JD, Connolly CN, Lummis SC, Lochner M..  (2012)  High-affinity fluorescent ligands for the 5-HT(3) receptor.,  22  (2): [PMID:22189135] [10.1016/j.bmcl.2011.11.097]

55. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

56. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM..  (2013)  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.,  56  (3): [PMID:23241029] [10.1021/jm301302s]

57. Del Cadia M, De Rienzo F, Weston DA, Thompson AJ, Menziani MC, Lummis SC..  (2013)  Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.,  21  (23): [PMID:24128813] [10.1016/j.bmc.2013.09.028]

58. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R..  (2004)  [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].,  28  (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2]

59. Loi CM, Smith DA, Dalvie D..  (2013)  Which metabolites circulate?,  41  (5): [PMID:23454828] [10.1124/dmd.112.050278]

60. WHO Anatomical Therapeutic Chemical Classification, 

61. British National Formulary (72nd edition), 

62. DrugMatrix,  [10.6019/CHEMBL3885881]

63. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W..  (2016)  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.,  21  (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015]

64. Unpublished dataset, 

65. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

66. Juza R, Vojtechova I, Stefkova-Mazochova K, Dehaen W, Petrasek T, Prchal L, Kobrlova T, Janousek J, Vlcek P, Mezeiova E, Svozil D, Karasova JZ, Pejchal J, Stark H, Satala G, Bojarski AJ, Kubacka M, Mogilski S, Randakova A, Musilek K, Soukup O, Korabecny J..  (2022)  Novel D₂/5-HT receptor modulators related to cariprazine with potential implication to schizophrenia treatment.,  232  [PMID:35176563] [10.1016/j.ejmech.2022.114193]

67. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

68. European Medicines Agency, 

Source

Source(10):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• DrugMatrix
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• Fraunhofer HDAC6
• European Medicines Agency